WO2001021201A3 - Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen - Google Patents

Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen Download PDF

Info

Publication number
WO2001021201A3
WO2001021201A3 PCT/GB2000/003601 GB0003601W WO0121201A3 WO 2001021201 A3 WO2001021201 A3 WO 2001021201A3 GB 0003601 W GB0003601 W GB 0003601W WO 0121201 A3 WO0121201 A3 WO 0121201A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
boost
replication
immune response
adenoviral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003601
Other languages
French (fr)
Other versions
WO2001021201A2 (en
Inventor
Joerg Schneider
Sarah Catherine Gilbert
Carolyn Mary Hannan
Adrian Vivian Sinton Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001021201(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE60020136T priority Critical patent/DE60020136T2/en
Priority to JP2001524625A priority patent/JP2003509470A/en
Priority to DK00960857T priority patent/DK1214416T3/en
Priority to CA002384806A priority patent/CA2384806A1/en
Priority to BR0014138-0A priority patent/BR0014138A/en
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to AU73024/00A priority patent/AU762894B2/en
Priority to AT00960857T priority patent/ATE295421T1/en
Priority to EP00960857A priority patent/EP1214416B1/en
Publication of WO2001021201A2 publication Critical patent/WO2001021201A2/en
Publication of WO2001021201A3 publication Critical patent/WO2001021201A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of a replication-deficient adenoviral vector encoding an antigen or a CD8+ T cell epitope of the antigen to boost in the individual a CD8+ T cell immune response to the antigen following prior administration of a priming composition. The priming composition comprises the antigen or epitope or nucleic acid encoding the antigen or epitope, and may be DNA, Ty-LVP'S or Modified Virus Ankara (MVA). Administration may be intradermal or intramuscular.
PCT/GB2000/003601 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen Ceased WO2001021201A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP00960857A EP1214416B1 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector in the manufacture of a medicament to boost cd8+ t cell immune response to antigen
JP2001524625A JP2003509470A (en) 1999-09-21 2000-09-20 Use of a replication-defective adenovirus vector to enhance a CD8 + T cell immune response to an antigen
DK00960857T DK1214416T3 (en) 1999-09-21 2000-09-20 Use of a replication-inhibited adenoviral vector to prepare a drug to stimulate the immune response to antigen in CD + T cells
CA002384806A CA2384806A1 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
BR0014138-0A BR0014138A (en) 1999-09-21 2000-09-20 Use of a replication-deficient adenoviral vector, and methods to enhance, and to induce, cd8 + t cell immune response to an antigen in an individual
DE60020136T DE60020136T2 (en) 1999-09-21 2000-09-20 USE OF A REPLICATION-DEFICIENT ADENOVIRAL VECTOR FOR THE PRODUCTION OF A MEDICAMENT FOR INCREASING THE CD8 + T-CELL IMMUNE RESPONSE AGAINST ANTIGEN
AU73024/00A AU762894B2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen
AT00960857T ATE295421T1 (en) 1999-09-21 2000-09-20 USE OF A REPLICATION-DEFICIENCY ADENOVIRAL VECTOR TO PRODUCE A MEDICATION TO INCREASE THE CD8+ T-CELL IMMUNE RESPONSE TO ANTIGEN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
GB9922361.2 1999-09-21

Publications (2)

Publication Number Publication Date
WO2001021201A2 WO2001021201A2 (en) 2001-03-29
WO2001021201A3 true WO2001021201A3 (en) 2001-10-18

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003601 Ceased WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Country Status (12)

Country Link
EP (2) EP1612269A1 (en)
JP (1) JP2003509470A (en)
CN (1) CN1391609A (en)
AT (1) ATE295421T1 (en)
AU (1) AU762894B2 (en)
BR (1) BR0014138A (en)
CA (1) CA2384806A1 (en)
DE (1) DE60020136T2 (en)
DK (1) DK1214416T3 (en)
ES (1) ES2241653T3 (en)
GB (1) GB9922361D0 (en)
WO (1) WO2001021201A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20050123561A1 (en) * 2002-05-20 2005-06-09 Mitsuo Honda Radio lan access authentication system
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
CN100410382C (en) * 2006-08-18 2008-08-13 上海交通大学医学院 Co-expression vector and eukaryotic expression vector capable of inducing cellular immune response
KR20090080941A (en) * 2006-11-17 2009-07-27 제네트로닉스, 인코포레이티드 Methods to boost immune response using vaccination and boosting using electroporation
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
EP2198020B1 (en) * 2007-09-14 2016-04-13 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
US9828414B2 (en) * 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
WO2021074648A1 (en) * 2019-10-16 2021-04-22 Cancer Research Technology Limited Vector for cancer treatment
EP4444347A1 (en) 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, WARNIER GUY ET AL: "Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.", XP002164103, Database accession no. PREV199699138086 *
GILBERT SARAH C ET AL: "A protein particle vaccine containing multiple malaria epitopes.", NATURE BIOTECHNOLOGY, vol. 15, no. 12, 1997, pages 1280 - 1283, XP002164101, ISSN: 1087-0156 *
HANKE T ET AL: "Immunogenicities of intravenous and intramuscular administration of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.", JOURNAL OF GENERAL VIROLOGY, vol. 79, no. 1, January 1998 (1998-01-01), pages 83 - 90, XP002164102, ISSN: 0022-1317 *
INTERNATIONAL JOURNAL OF CANCER, vol. 67, no. 2, 1996, pages 303 - 310, ISSN: 0020-7136 *
KAZANJI MIRDAD ET AL: "Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene.", INTERNATIONAL JOURNAL OF CANCER, vol. 71, no. 2, 1997, pages 300 - 307, XP000982098, ISSN: 0020-7136 *
NATUK ROBERT ET AL: "Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 9, no. 5, 1993, pages 395 - 404, XP000979583, ISSN: 0889-2229 *
SCHNEIDER JORG ET AL: "Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.", NATURE MEDICINE, vol. 4, no. 4, April 1998 (1998-04-01), pages 397 - 402, XP000739989, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
DE60020136D1 (en) 2005-06-16
BR0014138A (en) 2002-05-21
AU7302400A (en) 2001-04-24
GB9922361D0 (en) 1999-11-24
EP1214416A2 (en) 2002-06-19
EP1214416B1 (en) 2005-05-11
WO2001021201A2 (en) 2001-03-29
AU762894B2 (en) 2003-07-10
DK1214416T3 (en) 2005-08-29
CN1391609A (en) 2003-01-15
EP1612269A1 (en) 2006-01-04
ES2241653T3 (en) 2005-11-01
CA2384806A1 (en) 2001-03-29
ATE295421T1 (en) 2005-05-15
DE60020136T2 (en) 2006-02-23
JP2003509470A (en) 2003-03-11

Similar Documents

Publication Publication Date Title
WO2001021201A3 (en) Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
WO1998002546A3 (en) Dna immunization against chlamydia infection
WO1998056919A3 (en) Methods and reagents for vaccination which generate a cd8 t cell immune response
DK0835133T3 (en) Recombinant smallpox virus rabies and combination preparations and their uses
WO2000053767A3 (en) Nucleic acid respiratory syncytial virus vaccines
EP0278940A3 (en) Hepatitis b virus surface antigens and hybrid antigens containing them
WO1996040945A3 (en) Nucleic acid respiratory syncytial virus vaccines
WO2000073316A3 (en) Virus immunologic determinants
WO1998011244A3 (en) AAV4 vector and uses thereof
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
JP2003509470A5 (en)
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2002024730A3 (en) Transduction of dendritic cells using adenoviral vectors
AU2002319501A1 (en) Materials and methods relating to improved vaccination strategies
WO1999051745A3 (en) Dna immunization against chlamydia infection
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
ATE319833T1 (en) VACCINES TO INCREASE IMMUNE RESPONSES AGAINST HERPES SIMPLEX VIRUS
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
WO2001083737A3 (en) Porcine adenovirus type 5 vector and vaccine
WO2004024756A3 (en) Orthopoxvirus antigens and use thereof
WO2003075849A3 (en) Composition and method for enhancing immune response
WO2000066743A3 (en) Viral expression vectors
MXPA03010527A (en) Vaccine composition.
HK1046853A1 (en) Method and compositions for treating hepatocellular cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/341/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2384806

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 524625

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 73024/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000960857

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008159335

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10088677

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000960857

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 73024/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000960857

Country of ref document: EP